On Apr. 9, 2022, BioNTech announced it was granted a pandemic preparedness contract by the Federal Republic of Germany. Under the preparedness agreement, BioNTech will reserve and maintain manufacturing capabilities to produce at least 80 million mRNA-based vaccine doses per year. The contract has an initial term of five years.